Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodesix, Inc. (BDSX) SEC filings page on Stock Titan brings together the company’s official disclosures as a Nasdaq-listed diagnostic solutions company. Through its reports to the U.S. Securities and Exchange Commission, Biodesix provides detail on its diagnostic testing and development services businesses, capital structure, and material corporate events.
Investors can use this page to access current and historical filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe revenue from Lung Diagnostics and Development Services, operating metrics, and risk factors relevant to a diagnostics and health care business. These core filings typically discuss Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, as well as the company’s work with biopharmaceutical and life sciences partners.
Biodesix also files Forms 8-K to report specific material events. Recent 8-K filings document actions such as a one-for-twenty reverse stock split of the company’s common stock, the related amendment to its certificate of incorporation, elimination of a preferred stock series, and confirmation that the company regained compliance with Nasdaq’s minimum bid price requirement. Other 8-Ks furnish press releases announcing quarterly financial and operating results.
On this page, users can review insider and capital structure-related filings when available, including information about changes to equity, preferred stock designations, and other securities. These documents help clarify how corporate actions affect common stockholders and outstanding awards or warrants.
Stock Titan enhances access to Biodesix filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussions of revenue composition, diagnostic and development services, stock listing matters, and significant corporate changes. Real-time updates from the EDGAR system ensure that new Biodesix 10-K, 10-Q, 8-K, and related filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full regulatory text.
Biodesix, Inc. reported strong top-line growth for the quarter ended March 31, 2026, with revenue rising to $25.6 million from $18.0 million a year earlier, driven by both lung diagnostic tests and development services. Operating loss narrowed to $6.2 million, and net loss improved to $7.8 million from $11.1 million, as higher revenue offset increased sales, marketing, and R&D expenses.
Cash and cash equivalents increased to $25.6 million from $19.1 million at the prior year-end, helped by an at-the-market equity raise of about $17.2 million in gross proceeds. Total assets reached $94.6 million, and stockholders’ equity turned positive at $9.1 million versus a prior deficit, partly reflecting new capital and warrant-related equity. Biodesix also extended its $50.0 million Perceptive term loan maturity to November 2028, keeping an interest-only structure but issuing additional equity warrants as consideration.
Biodesix, Inc. reported strong first quarter 2026 results with total revenue of $25.6 million, up 42% year over year, driven by growth in both Diagnostic Testing and Development Services. Diagnostic Testing revenue reached $22.3 million on 29% higher test volumes and better average revenue per test, while Development Services revenue nearly doubled to $3.3 million.
Gross margin was 84% in the quarter, or 82% excluding a one‑time $0.4 million tax recovery, about a 300‑basis‑point improvement from a year earlier. Operating expenses rose 18% to $27.6 million as the company invested in sales, marketing, and G&A, including $1.1 million of share-based compensation. Net loss improved to $7.8 million from $11.1 million, and Adjusted EBITDA loss narrowed to $4.1 million from $6.2 million.
Cash and cash equivalents increased to $25.6 million from $19.0 million at year end, helped by $16.8 million of at-the-market net proceeds. Reflecting the strong start to the year, Biodesix raised its 2026 total revenue outlook to $108–114 million, with the midpoint implying about 25% growth over 2025, and continues to target progress toward Adjusted EBITDA profitability.
Biodesix, Inc. (Common Stock) has a Schedule 13G filed showing AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman beneficially own 758,328 shares, representing 7.7% of the outstanding common stock as of 03/31/2026. The filing states the Reporting Persons have sole voting and sole dispositive power over these shares.
Biodesix, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on May 19, 2026 at 1:00 p.m. Mountain Time. Stockholders of record on March 23, 2026, when 10,107,219 common shares were outstanding, may vote online on four key proposals.
These proposals are the election of two Class III directors to serve until 2029, a non-binding advisory vote on 2025 compensation for named executive officers, an advisory vote on how often to hold future say‑on‑pay votes (the board recommends every one year), and ratification of KPMG LLP as independent auditor for 2026.
The proxy also outlines Biodesix’s board structure, committee membership, director and executive pay (including 2025 salary increases, cash bonuses and equity awards) and new severance and change‑in‑control agreements for senior executives, together with stock ownership, equity plan data and pay‑versus‑performance disclosures.
Biodesix Inc. chairman John Patience exercised restricted stock units into common shares on March 31, 2026. He converted 1,361 RSUs into 1,361 shares of common stock at an exercise price of $0.00 per share. Following the transactions, he directly holds 24,022 common shares and 4,082 RSUs, with additional indirect holdings through Patience Enterprises LP, the John Patience Living Trust, and his spouse.
Biodesix, Inc. reports strong 2025 growth as a lung‑focused diagnostics company. The business generated an estimated $88.5 million in total revenue, up 24% from 2024, driven mainly by its Biodesix Lung Diagnostic Testing segment.
Lung Diagnostic Testing produced $79.2 million of revenue from about 62,600 tests, increases of 22% and 15%, while Development Services contributed $9.3 million, up 41%. Gross margin improved to 81% from 78% as the company emphasized operational efficiencies and cost discipline, limiting operating expense growth (excluding direct costs and expenses) to 10% while revenue rose 24%.
Biodesix offers five blood‑based lung tests spanning nodule diagnosis, treatment guidance and monitoring, and estimates over 10 million annual testing opportunities in the U.S. representing a market of more than $27 billion. The company highlights expanding clinical data, growing reimbursement coverage, and multiple ongoing clinical studies, while operating CLIA‑certified, CAP‑accredited laboratories and maintaining an extensive intellectual property portfolio.
Biodesix reported strong fourth-quarter and full-year 2025 results, highlighted by rapid growth and improving profitability metrics. Q4 revenue reached $28.8 million, up 41%, with gross margin expanding to 83%. For 2025, total revenue was $88.5 million and gross margin was 81%, reflecting operating scale in its lung-focused diagnostics and development services businesses.
Net loss narrowed to $4.0 million in Q4 and $35.3 million for 2025, while Adjusted EBITDA turned positive at $0.5 million in Q4 and improved to a $17.5 million loss for the year. The company ended 2025 with $19.0 million in cash and subsequently raised an additional $14.7 million and extended its senior term loan maturity to November 2028. For 2026, Biodesix guides revenue between $106 million and $112 million, with the midpoint implying about 23% growth and continued progress toward sustained Adjusted EBITDA profitability.
Biodesix Chief Development Officer Gary Anthony Pestano reported RSU vesting and a related tax sale. On February 20, 1,528 Restricted Stock Units were exercised into 1,528 shares of Biodesix common stock at $0.00 per share, as part of an annual vesting schedule starting February 20, 2025.
On February 23, 556 shares of common stock were sold at a weighted average price of $12.7756 per share by the issuer's broker to cover taxes due upon RSU vesting for certain employees, including Pestano. After these transactions, Pestano directly held 10,359 shares of common stock and 4,582 RSUs, which continue to vest in four equal annual installments.
Biodesix Inc.'s Chief Commercial Officer Kieran O'Kane reported insider transactions involving common stock and restricted stock units. On February 23, 2026, he sold 535 shares of common stock in an open-market transaction at a weighted average price of $12.7756 per share to cover taxes upon the vesting of restricted stock units. These shares were sold by the issuer's broker in multiple trades between $12.58 and $13.16 per share. On February 20, 2026, 1,469 restricted stock units were exercised and converted into 1,469 shares of common stock at $0.00 per share. Following these transactions, O'Kane held 9,819 shares of common stock and 4,406 restricted stock units, after adjustments for a one-for-twenty reverse stock split effective September 15, 2025. The RSUs vest in four equal annual installments starting February 20, 2025, generally conditioned on continued service.